Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
|
Jul 2020
|
Blood
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria
|
Jun 2015
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
|
Jul 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life
|
Jan 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia
|
Oct 2014
|
Blood
|
aplastic anemia
|
Cyclophosphamide in severe aplastic anemia?
|
Oct 2014
|
Blood
|
aplastic anemia
|
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
|
Sep 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
|
Apr 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes
|
Jun 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|